Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 2201 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 15 |
| 2202 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 17 |
| 2203 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 81 |
| 2204 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 29 |
| 2205 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 15 |
| 2206 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2023 | Standard Therapy | Poland | 1 |
| 2207 | Bone Marrow | Allogeneic | Sickle Cell Disease | Hematology | 2023 | Standard Therapy | Poland | 5 |
| 2208 | Bone Marrow | Allogeneic | T-Acute Lymphoblastic Leukemia, Ataxia Telangiectasia | Hematology | 2023 | Standard Therapy | Poland | 8 |
| 2209 | Bone Marrow | Allogeneic | T-Cell Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 16 |
| 2210 | Bone Marrow | Allogeneic | Thalassemia Major | Hematology | 2023 | Standard Therapy | Poland | 2 |
| 2211 | Bone Marrow | Allogeneic | Very Severe Aplastic Anemia | Hematology | 2023 | Standard Therapy | Poland | 21 |
| 2212 | Bone Marrow | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2023 | Standard Therapy | Poland | 1 |
| 2213 | Bone Marrow | Allogeneic | Wiskott-Aldrich Syndrome | Hematology | 2023 | Standard Therapy | Poland | 3 |
| 2214 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 67 |
| 2215 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 37 |
| 2216 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 47 |
| 2217 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 16 |
| 2218 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 58 |
| 2219 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2220 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 66 |
| 2221 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 11 |
| 2222 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 8 |
| 2223 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 52 |
| 2224 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 51 |
| 2225 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 54 |
| 2226 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2227 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 40 |
| 2228 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 60 |
| 2229 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 40 |
| 2230 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 51 |
| 2231 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 35 |
| 2232 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 65 |
| 2233 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 47 |
| 2234 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 39 |
| 2235 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2236 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 37 |
| 2237 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2238 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 19 |
| 2239 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 20 |
| 2240 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 37 |
| 2241 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 42 |
| 2242 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 48 |
| 2243 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 47 |
| 2244 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 64 |
| 2245 | Apheresis | Autologous | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 61 |
| 2246 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 20 |
| 2247 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 65 |
| 2248 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 40 |
| 2249 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2250 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 44 |
| 2251 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 54 |
| 2252 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Germany | 31 |
| 2253 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 30 |
| 2254 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2255 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia T-Cell; Myelodysplastic Syndrome | Hematology | 2023 | Standard Therapy | Poland | 72 |
| 2256 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Germany | 58 |
| 2257 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Germany | 60 |
| 2258 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 32 |
| 2259 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 28 |
| 2260 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2261 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 70 |
| 2262 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 50 |
| 2263 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 64 |
| 2264 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2265 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 41 |
| 2266 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2267 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 63 |
| 2268 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 38 |
| 2269 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2270 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2271 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 2272 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 87 |
| 2273 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 71 |
| 2274 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2275 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 47 |
| 2276 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 46 |
| 2277 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 56 |
| 2278 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 46 |
| 2279 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 33 |
| 2280 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 53 |
| 2281 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2282 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 69 |
| 2283 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 38 |
| 2284 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 57 |
| 2285 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 1 |
| 2286 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 28 |
| 2287 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2288 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2289 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 62 |
| 2290 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 60 |
| 2291 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 31 |
| 2292 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 67 |
| 2293 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 73 |
| 2294 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 82 |
| 2295 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 73 |
| 2296 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2297 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 59 |
| 2298 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 72 |
| 2299 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 55 |
| 2300 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2023 | Standard Therapy | Poland | 41 |